SAN

102.7

+0.14%↑

EI

267.6

+0.26%↑

SHL.DE

50.02

-0.52%↓

FRE

39.5

+0.36%↑

PHIA

23.56

+1.12%↑

SAN

102.7

+0.14%↑

EI

267.6

+0.26%↑

SHL.DE

50.02

-0.52%↓

FRE

39.5

+0.36%↑

PHIA

23.56

+1.12%↑

SAN

102.7

+0.14%↑

EI

267.6

+0.26%↑

SHL.DE

50.02

-0.52%↓

FRE

39.5

+0.36%↑

PHIA

23.56

+1.12%↑

SAN

102.7

+0.14%↑

EI

267.6

+0.26%↑

SHL.DE

50.02

-0.52%↓

FRE

39.5

+0.36%↑

PHIA

23.56

+1.12%↑

SAN

102.7

+0.14%↑

EI

267.6

+0.26%↑

SHL.DE

50.02

-0.52%↓

FRE

39.5

+0.36%↑

PHIA

23.56

+1.12%↑

Search

Argenx SE

Open

BrancheGesundheitswesen

545 0.48

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

532.4

Max

548.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

690M

774M

Verkäufe

165M

738M

KGV

Branchendurchschnitt

47.333

73.239

EPS

0.72

Gewinnspanne

104.841

Angestellte

1,599

EBITDA

126M

89M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

-2.07% downside

Dividenden

By Dow Jones

Nächstes Ergebnis

8. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2B

34B

Vorheriger Eröffnungskurs

544.52

Vorheriger Schlusskurs

545

Nachrichtenstimmung

By Acuity

70%

30%

339 / 386 Ranking in Healthcare

Argenx SE Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. März 2025, 22:45 UTC

Top News

Intel's New CEO Plots Turnaround; 'We Need to Improve'

31. März 2025, 23:54 UTC

Market Talk

Nikkei May Rise After Monday's Selloff -- Market Talk

31. März 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

31. März 2025, 23:15 UTC

Market Talk

Tower Shares Ease After Bain Capital Exit -- Market Talk

31. März 2025, 23:15 UTC

Market Talk

Global Equities Roundup: Market Talk

31. März 2025, 22:33 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

31. März 2025, 22:28 UTC

Ergebnisse

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

31. März 2025, 22:28 UTC

Ergebnisse

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

31. März 2025, 22:28 UTC

Ergebnisse

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

31. März 2025, 22:28 UTC

Ergebnisse

China Vanke Swings to Loss for 2024 >000002.SZ

31. März 2025, 21:47 UTC

Top News

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

31. März 2025, 21:44 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

31. März 2025, 21:21 UTC

Market Talk

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

31. März 2025, 21:18 UTC

Top News

Copper Is 2025's Hottest Commodity -- Update

31. März 2025, 21:09 UTC

Top News

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

31. März 2025, 21:02 UTC

Ergebnisse

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

31. März 2025, 21:01 UTC

Ergebnisse

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

31. März 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

31. März 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. März 2025, 20:37 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

31. März 2025, 20:17 UTC

Top News

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

31. März 2025, 20:13 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

31. März 2025, 20:03 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

31. März 2025, 19:09 UTC

Market Talk

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

31. März 2025, 18:56 UTC

Market Talk

U.S. Natural Gas Gains With Help From Weather -- Market Talk

31. März 2025, 18:54 UTC

Market Talk

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

31. März 2025, 18:40 UTC

Market Talk

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

31. März 2025, 18:34 UTC

Market Talk

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

31. März 2025, 18:28 UTC

Market Talk

Gold Climbs to Close Out Quarter -- Market Talk

31. März 2025, 18:03 UTC

Top News

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Peer-Vergleich

Kursveränderung

Argenx SE Prognose

Kursziel

By TipRanks

-2.07% Nachteil

12-Monats-Prognose

Durchschnitt 438.33 EUR  -2.07%

Hoch 545 EUR

Tief 223 EUR

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Argenx SE – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

5

Buy

0

Halten

1

Sell

Stimmung

By Acuity

339 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.